Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 10,556 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: HIV Infections
Interventions: BMS-936559, Placebo for BMS-936559; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more

Conditions: Overweight, Type 2 Diabetes, Obesity
Interventions: Petrelintide, Placebo; Drug · Other
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 48
States / cities: Cullman, Alabama • Chandler, Arizona • Phoenix, Arizona + 43 more

Conditions: Carcinoma, Small Cell
Interventions: Topotecan, carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 16
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 13 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 16
States / cities: Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

Conditions: Breast Cancer Female
Interventions: Internet-based Intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 236
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more

Conditions: Diabetes Mellitus
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 29
States / cities: Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Efavirenz; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Follicular Lymphoma
Interventions: Tazemetostat, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Fountain Valley, California • Boulder, Colorado + 17 more

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 90
States / cities: Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 87 more

Conditions: Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 77
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Major Depressive Disorder
Interventions: tasimelteon, placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Garden Grove, California • Irvine, California • Los Alamitos, California + 36 more

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Fullerton, California • Peoria, Illinois • The Bronx, New York + 1 more

Conditions: Medication Reconciliation
Interventions: PictureRx medication history platform; Other
Lead sponsor: PictureRx, LLC; Other
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Crohn's Disease
Interventions: Nitazoxanide, Placebo; Drug · Other
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Tampa, Florida • Zephyrhills, Florida • Marietta, Georgia + 10 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim, Placebo, PARI eFlow nebulizer system; Drug · Device
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio

Conditions: Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 2,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 175
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Diclofenac, Celecoxib, Matching placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 71
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 114
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more

Conditions: Multiple Myeloma, Myeloma
Interventions: FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more

Conditions: Pelvic Organ Prolapse
Interventions: Restorelle Direct Fix A, Restorelle Direct Fix P, Native Tissue Repair Anterior, Native Tissue Repair Posterior; Device · Procedure
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 33
States / cities: Agoura Hills, California • Stanford, California • Denver, Colorado + 30 more

Search by objective public record fields.

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

aHUS Observational Long Term Follow-Up

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

PictureRx: Improving Medication Safety in Health Disparity Populations

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

FT576 in Subjects With Multiple Myeloma

Restorelle® Mesh Versus Native Tissue Repair for Prolapse